Clinical trial of travoprost ophthalmic solution in the treatment of primary open-angle glaucoma
10.13699/j.cnki.1001-6821.2017.04.007
- VernacularTitle:曲伏前列素滴眼液治疗原发性开角型青光眼的临床研究
- Author:
Jia YING
1
;
Yan-Xia ZHU
;
Xiu-Zhen ZHANG
;
Song-Ping YU
Author Information
1. 丽水市中心医院眼科
- Keywords:
travoprost ophthahmic solution;
levobunolol hydrochloride;
primary open-angle glaucoma;
blood rheology
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(4):312-315
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect and safety of travoprost ophthahmic solution in treatment of primary open-angle glaucoma (POAG).Methods A total of 78 patients with POAG were randomly divided into treatment group and control group,each group contained 39 cases.Treatment group was given travoprost ophthahmic solution,one drop each time,once a day;the control group was treated with levobunolol hydrochloride,one drop each time,twice a day (morning and night).The treatment last for 3 months.The changes of intraocular pressure (IOP) and hemorheology were compared between the two groups before treatment,one month and three months after treatment,and the adverse drug reactions were observed.Results After 1 month of treatment,the diurnal intraocular pressure(at 7:00) of treatment group and control group were (15.51 ± 2.11),(15.42 ± 2.14) mmHg respectively;Before treatment,the levels were (24.98 ± 3.24),(25.24 ± 3.15) mmHg,with statistical significance(P ＜ 0.05).At 3 months after the treatment,the intraocular pressure (IOP) of the treatment group was (15.16 ± 3.25) mmHg while that of the control group was (16.98 ± 3.47) mmHg at 21:00,and the difference was significant (P ＜ 0.05).After treatment,the high-shear whole blood viscosity,low shear whole blood viscosity,hematocrit,plasma viscosity and fibrinogen index of the treatment group were (5.02 ± 1.01) mPa · s,(7.05 ± 1.11)mPa · s,(38.57 ±6.15)％,(1.46 ±0.16) mPa · s,(2.58 ±0.65) g · L-1,while those of the control group were (5.97±1.31) mPa · s,(8.54 ± 1.22) mPa · s,(42.31 ±7.42) mPa · s,(1.57 ±0.18) mPa · s and (3.43 ± 0.71) mPa · s,with significant differences (P ＜ 0.05).In the treatment group,2 patients suffered from the adverse effects of eyelash growth,4 cases of conjunctival congestion,1 case of ocular pain,1 case of abdominal spastic pain,the incidence of adverse drug reactions was 20.51％ (8/29 cases);In the control group,2 cases of adverse reactions in patients with heart rate slowing,2 cases of dry eye,4 cases of transient burning sensation,the incidence of adverse drug reactions was 20.51％ (8/29 cases).The incidence of adverse reactions in the two groups was not statistically significant difference (P ＞ 0.05).Conclusion The efficacy of travoprost ophthahmic solution is better than that of levobunolol hydrochloride,which includes the control of intraocular pressure at night,improvement of blood rheology as well as stability with high safety.
